Literature DB >> 15534441

Sperm washing, use of HAART and role of elective Caesarean section.

Augusto E Semprini1, Alessandra Vucetich, Lital Hollander.   

Abstract

PURPOSE OF REVIEW: Today, 50% of people living with HIV are women and most have been sexually infected. Highly active antiretroviral therapy (HAART) reduces the rates of both sexual and vertical infection, but maximum protection is achieved with sperm washing and elective Caesarean section. RECENT
FINDINGS: Men taking HAART have lower seminal concentration of HIV, and sexual transmission may be reduced. However, a certain percentage of aviraemic men retain viral presence in semen, and unprotected intercourse to achieve fertilization must be discouraged as it carries the risk of sexual transmission of the virus. HIV-discordant couples should be informed that sperm washing can remove HIV from semen, allowing conception without the risk of infection for the seronegative female and eventually the child. In HIV-positive women, perinatal transmission of HIV can be curtailed to less than 2% by using HAART to decrease maternal viral load and offering prenatal preexposure prophylaxis of the fetus, and elective Caesarean section. Each intervention carries specific risks and benefits. The contribution of each preventive arm in achieving fetal protection can only be crudely measured and optimal obstetric management must involve discussion with the pregnant woman of the pros and cons of each strategy.
SUMMARY: In HIV-positive men taking HAART, seminal viral load is decreased but not eliminated and fertilization should be achieved through sperm washing to offer maximum protection for the uninfected female. Pregnant HIV-positive women on antiretroviral medication have a reduced risk of transmitting the virus, but should still be counselled about the possibility to further limit the chances of infecting their infant through elective Caesarean section.

Entities:  

Mesh:

Year:  2004        PMID: 15534441     DOI: 10.1097/00001703-200412000-00005

Source DB:  PubMed          Journal:  Curr Opin Obstet Gynecol        ISSN: 1040-872X            Impact factor:   1.927


  8 in total

Review 1.  Safer conception interventions for HIV-affected couples: implications for resource-constrained settings.

Authors:  Rachelle J Chadwick; Joanne E Mantell; Jennifer Moodley; Jane Harries; Virginia Zweigenthal; Diane Cooper
Journal:  Top Antivir Med       Date:  2011-11

2.  Fertility Desires and Intentions and the Relationship to Consistent Condom Use and Provider Communication Regarding Childbearing Among HIV Clients in Uganda.

Authors:  Glenn J Wagner; Rhoda Wanyenze
Journal:  ISRN Infect Dis       Date:  2013

Review 3.  Update: preventing mother-to-child transmission of HIV.

Authors:  Mary A Vogler
Journal:  Curr HIV/AIDS Rep       Date:  2006-07       Impact factor: 5.071

4.  Reproductive health options among HIV-infected persons in the low-income Niger Delta of Nigeria.

Authors:  Osaro Erhabor; Chris I Akani; Cosmos E Eyindah
Journal:  HIV AIDS (Auckl)       Date:  2012-02-09

5.  Changes in Providers' Self-Efficacy and Intentions to Provide Safer Conception Counseling Over 24 Months.

Authors:  Kathy Goggin; Emily A Hurley; Glenn J Wagner; Vincent Staggs; Sarah Finocchario-Kessler; Jolly Beyeza-Kashesya; Deborah Mindry; Josephine Birungi; Rhoda K Wanyenze
Journal:  AIDS Behav       Date:  2018-09

6.  HIV in semen: still more to be learned.

Authors:  Pietro L Vernazza
Journal:  AIDS Res Ther       Date:  2005-12-03       Impact factor: 2.250

7.  Natural conception in HIV-serodiscordant couples with the infected partner in suppressive antiretroviral therapy: A prospective cohort study.

Authors:  Jorge Del Romero; María Begoña Baza; Isabel Río; Adrián Jerónimo; Mar Vera; Victoria Hernando; Carmen Rodríguez; Jesús Castilla
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

8.  Fertility and contraceptive decision-making and support for HIV infected individuals: client and provider experiences and perceptions at two HIV clinics in Uganda.

Authors:  Rhoda K Wanyenze; Glenn J Wagner; Nazarius M Tumwesigye; Maria Nannyonga; Fred Wabwire-Mangen; Moses R Kamya
Journal:  BMC Public Health       Date:  2013-02-02       Impact factor: 3.295

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.